ArticleCureus2024
Relationship Between T-helper 1 Inflammatory Biomarkers and Hematological Index Responses in Patients With Multiple Sclerosis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Multiple sclerosis is a chronic, progressive, disabling disease associated with a high rate of infection, evidence of chronic inflammation, and a high mortality rate. Abnormalities of serum cytokines and changes in the activity of inflammatory cells were associated with relapsing-remitting multiple sclerosis (MS-RR). This study aims to introduce new inflammatory ratios derived from hematological and lipid indices as discriminators of T-helper (Th)-1/Th-2 activity in RR-MS. Methods This cross-sectional study recruited 40 RR-MS patients and 30 healthy individuals. Th-1 and Th-2 cytokines, including interferon-y (INF-γ), tumor necrosis factor-a (TNF-α), interleukin (IL)-4, IL5, and IL-10 measurements, were performed using enzyme-linked immunosorbent assay technique. Hematological indices and lipid profiles were measured as routine laboratory investigations. SPSS Statistics version 20 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.) was used for data analysis. An independent sample t-test was used to compare two means, and Spearman correlation was used to assess the correlation between different markers. A p-value of <0.05 was considered statistically significant. Results Serum levels of Th-1 and Th-2 cytokines in RR-MS were significantly higher than in healthy subjects (p<0.001). The ratios of INF-γ-to-IL4 and TNF-α-to-IL-10 were significantly lower than the corresponding ratios of healthy subjects (p<0.001). Monocyte-to-high-density lipoprotein ratio (MHDLR) is significantly lower (p<0.001) than healthy subjects (9.4±1.62 vs. 6.4±1.1, respectively) and significantly correlated positively with INF-γ (r=0.417) and TNF-α (r=0.565), while MHDLR inversely correlated with IL-4 (r=-0.445) and IL-5 (r =-0.386). Lymphocyte-to-non-high-density lipoprotein ratio (LNHDLR) is significantly (p<0.001) higher than healthy subjects (18.2±3.3 vs. 13.1±2.2, respectively) and significantly correlated inversely with INF-γ (r=-0.484) and TNF-α (r=-0.456), while LNHDLR positively correlated with IL-4 (r=0.565) and IL-5 (r=0.532). The area under the curve (AUC) of MHDLR mimics the AUCs of Th-1 cytokines, while the AUC of LNHDLR mimics the AUCs of Th-2 cytokines. Conclusions MHDLR and LNHDLR served as pro-inflammatory and anti-inflammatory markers, respectively, with profiles similar to TH-1 and Th-2 cytokines. These findings suggest that these lipid-related ratios are non-invasive, cost-effective biomarkers for monitoring RR-MS patients' immune response and inflammatory status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.